CHARMAINE GRANT: Open Payments
NPI 1659921625 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,001 in 48 payments from 19 companies in 2025. Trend: 2023 $333 · 2024 $957 · 2025 $1,001
Food & beverage: $988Education: $13
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 5 | $139 |
| Celgene Corporation | 5 | $135 |
| Novartis Pharmaceuticals Corporation | 5 | $98 |
| PFIZER INC. | 5 | $92 |
| Daiichi Sankyo Inc. | 4 | $86 |
| Incyte Corporation | 3 | $67 |
| ARRAY BIOPHARMA INC | 7 | $46 |
| Eisai Inc. | 2 | $42 |
| Genentech USA, Inc. | 2 | $40 |
| GENZYME CORPORATION | 1 | $32 |
Products named: REBLOZYL, SCEMBLIX, BRAFTOVI, Enhertu, JAKAFI, Lenvima, Tecentriq, Vanflyta.
Industry payments across GA — which companies pay providers there.
